Patents by Inventor Rona Ortenberg

Rona Ortenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSESSMENT OF CEACAM1 EXPRESSION ON TUMOR INFILTRATING LYMPHOCYTES
    Publication number: 20240092934
    Abstract: Provided are methods and compositions comprising antibodies capable of specific binding to human CEACAM1 molecules, for treating and diagnosing cancer as well as assessing CEACAM1 expression in tumor infiltrating immune cells (TILs) in a biological sample obtained from a [cancer] subject.
    Type: Application
    Filed: November 24, 2023
    Publication date: March 21, 2024
    Applicant: FAMEWAVE LTD.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Rona ORTENBERG, Jacob SCHACHTER, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
  • Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
    Patent number: 11891453
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: February 6, 2024
    Assignee: FAMEWAVE LTD.
    Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
  • Humanized antibodies against CEACAM1
    Patent number: 11866509
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: January 9, 2024
    Assignee: FAMEWAVE LTD.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
  • Polynucleotides encoding humanized antibodies against CEACAM1
    Patent number: 11427647
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: August 30, 2022
    Assignee: FAMEWAVE LTD.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
  • ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE (CEACAM)
    Publication number: 20210070884
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Application
    Filed: September 29, 2020
    Publication date: March 11, 2021
    Applicant: Famewave Ltd.
    Inventors: Gal MARKEL, Tehila BEN MOSHE, Yair SAPIR, Ilana MANDEL, Jacob SCHACHTER, Rona ORTENBERG
  • HUMANIZED ANTIBODIES AGAINST CEACAM1
    Publication number: 20200277398
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 3, 2020
    Applicant: Famewave Ltd.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
  • HUMANIZED ANTIBODIES AGAINST CEACAM1
    Publication number: 20200216557
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Application
    Filed: December 2, 2019
    Publication date: July 9, 2020
    Applicant: Famewave Ltd.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
  • Humanized antibodies against CEACAM1
    Patent number: 10550196
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: February 4, 2020
    Assignee: Famewave Ltd.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
  • ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME
    Publication number: 20180016338
    Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
    Type: Application
    Filed: September 26, 2017
    Publication date: January 18, 2018
    Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Gal MARKEL, Rona ORTENBERG, Jacob SCHACHTER
  • ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE (CEACAM)
    Publication number: 20170355781
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Application
    Filed: August 22, 2017
    Publication date: December 14, 2017
    Applicant: CCAM BIOTHERAPEUTICS LTD.
    Inventors: Gal MARKEL, Tehila BEN MOSHE, Yair SAPIR, Ilana MANDEL, Jacob SCHACHTER, Rona ORTENBERG
  • Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
    Patent number: 9771431
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: September 26, 2017
    Assignee: CCAM BIOTHERAPEUTICS LTD.
    Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
  • HUMANIZED ANTIBODIES AGAINST CEACAM1
    Publication number: 20170044270
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: CCAM BIOTHERAPEUTICS LTD.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
  • ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME
    Publication number: 20160176966
    Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
    Type: Application
    Filed: January 8, 2016
    Publication date: June 23, 2016
    Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Gal Markel, Rona Ortenberg, Jacob Schachter
  • Anti CEACAM1 antibodies and methods of using same
    Patent number: 9261507
    Abstract: A method for diagnosing a cancer characterized by over expression of CEACAM1 using an anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1 and comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: February 16, 2016
    Assignees: Tel Hashomer Medical Research Infrastructure and Services LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Gal Markel, Rona Ortenberg, Jacob Schachter
  • ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE (CEACAM)
    Publication number: 20140271618
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Application
    Filed: October 10, 2012
    Publication date: September 18, 2014
    Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., CCAM BIOTHERAPEUTICS LTD.
    Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
  • ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME
    Publication number: 20140120554
    Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
    Type: Application
    Filed: October 23, 2013
    Publication date: May 1, 2014
    Applicants: RAMOT AT TEL AVIV UNIVERSITY LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Gal MARKEL, Rona ORTENBERG
  • Anti CEACAM1 antibodies and methods of using same
    Patent number: 8598322
    Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: December 3, 2013
    Assignees: Tel Hashomer Medical Research Infrastucture and Services Ltd., Ramot At Tel Aviv University Ltd.
    Inventors: Gal Markel, Rona Ortenberg
  • ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME
    Publication number: 20120100158
    Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
    Type: Application
    Filed: April 29, 2010
    Publication date: April 26, 2012
    Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Gal Markel, Rona Ortenberg